Abstract Number: 1533 • ACR Convergence 2023
Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study
Background/Purpose: Rituximab(RTX) has been used for the management of systemic sclerosis(SSc). Its efficacy has been recently confirmed in a phase III clinical trial with extension…Abstract Number: 0006 • ACR Convergence 2023
Preclinical Characterization of a Novel anti-CD40 Antagonist Antibody-glucocorticoid Conjugate with Superior Preclinical Efficacy and Favorable Safety Profile
Background/Purpose: Glucocorticoids (GCs) are the first-line anti-inflammatory treatment for many autoimmune diseases, but long-term systemic administration of GCs is associated with unwanted side effects, which…Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…Abstract Number: 0007 • ACR Convergence 2023
Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Background/Purpose: B cells have gained increased interest in ANCA-associated vasculitis (AAV) research, as the treatment of this autoimmune disease with rituximab (an anti-CD20 B cell…Abstract Number: 0784 • ACR Convergence 2023
Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial
Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…Abstract Number: 1813 • ACR Convergence 2023
Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
Background/Purpose: Data on cellular and humoral immunogenicity triggered by SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases (ARD) are limited. While current vaccine efforts have…Abstract Number: 0089 • ACR Convergence 2023
Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases
Background/Purpose: In healthy individuals, CD8 Treg activation leads to selective elimination of aberrantly activated self-reactive CD4 T cells to maintain immune balance. The CD8 Treg…Abstract Number: 0904 • ACR Convergence 2023
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Background/Purpose: A significant unmet need remains in the treatment of relapsed and/or refractory B cell-driven autoimmune diseases, including systemic lupus erythematosus (SLE),systemic sclerosis (SSc), and…Abstract Number: 1928 • ACR Convergence 2023
Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…Abstract Number: 0204 • ACR Convergence 2023
Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases
Background/Purpose: Literature data on the increased risk of severe infection regarding hypogammaglobinemia related to RTX in IMID are controversial and sparse. We proposed to evaluate…Abstract Number: 0910 • ACR Convergence 2023
17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
Background/Purpose: While systemic lupus erythematosus (SLE) disproportionally affects women versus men, elevation in estradiol (E2) alone is not sufficient to promote the development of autoantibody…Abstract Number: 1956 • ACR Convergence 2023
Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis
Background/Purpose: Autoimmune myositis involves a spectrum of rare autoimmune disorders characterized by inflammation and damage to skeletal muscles. The management of these challenging conditions often…Abstract Number: 0222 • ACR Convergence 2023
Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab
Background/Purpose: Rituximab (RTX) is widely used in immune mediated inflammatory disease (IMID) patients refractory to conventional treatment. Previous studies have indicated that RTX in IMID…Abstract Number: 0926 • ACR Convergence 2023
Single-cell Multi-Omic Evaluation of Differences in Immune Cell Populations in Progression Toward Systemic Lupus Erythematosus
Background/Purpose: Several groups of individuals are at higher risk for SLE, including those with African American ancestry (AA), lupus-associated autoantibodies (ANA+), or some clinical symptoms…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »